22nd Sep 2020 19:35
Open Orphan PLC - pharmaceutical services company - Paris subsidiary Venn Life Sciences secures "important" support contract with European pharmaceutical firm. Venn to assist with a longitudinal study, which will enrol over 750 patients. "This contract reinforces Venn's position as one of the leading providers of data-management, statistics and medical writing services to many of Europe's leading pharmaceutical and biotech companies," notes Open Orphan.
Current stock price: 14.75 pence
Year-to-date change: up sharply from 4.55p
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ORPH.L